A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
BOSS, D. S, GLEN, H, SCHELLENS, Jhm, EVANS, Trj, BEIJNEN, J. H, KEESEN, M, MORRISON, R, TAIT, B, COPALU, W, MAZUR, A, WANDERS, J, O'BRIEN, J. P
Published in British journal of cancer (08.05.2012)
Published in British journal of cancer (08.05.2012)
Get full text
Journal Article
Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors
Boss, D.S., Witteveen, P.O., van der Sar, J., Lolkema, M.P., Voest, E.E., Stockman, P.K., Ataman, O., Wilson, D., Das, S., Schellens, J.H.
Published in Annals of oncology (01.02.2011)
Published in Annals of oncology (01.02.2011)
Get full text
Journal Article
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
Boss, D.S., Schwartz, G.K., Middleton, M.R., Amakye, D.D., Swaisland, H., Midgley, R.S., Ranson, M., Danson, S., Calvert, H., Plummer, R., Morris, C., Carvajal, R.D., Chirieac, L.R., Schellens, J.H.M., Shapiro, G.I.
Published in Annals of oncology (01.04.2010)
Published in Annals of oncology (01.04.2010)
Get full text
Journal Article
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer
van der Noll, R., Smit, W. M., Wymenga, A. N. M., Boss, D. S., Grob, M., Huitema, A. D. R., Rosing, H., Tibben, M. M., Keessen, M., Rehorst, H., Beijnen, J. H., Schellens, J. H. M.
Published in Investigational new drugs (01.12.2015)
Published in Investigational new drugs (01.12.2015)
Get full text
Journal Article
Assessment of clinical activity of E7080, a multitargeted kinase inhibitor, in patients with advanced melanoma treated in two phase I trials
Hong, D. S., Boss, D. S., Glen, H., Mink, J., Ren, M., Andresen, C., O'Brien, J. P., Kurzrock, R., Schellens, J. H. M., Nemunaitis, J. J., Evans, T. R. J.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
Phase I, pharmacokinetic, and pharmacodynamic study of carboplatin and topotecan administered in two different schedules
Boss, D. S., Siegel-Lakhai, W. S., Schoemaker-van Egmond, N. E., Pluim, D., Rosing, H., Ten Bokkel-Huinink, W. W., Beijnen, J. H., Schellens, J. H.
Published in Journal of clinical oncology (20.05.2009)
Published in Journal of clinical oncology (20.05.2009)
Get full text
Journal Article
First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers
Yap, T. A., Boss, D. S., Fong, P. C., Roelvink, M., Tutt, A., Carmichael, J., O’Connor, M. J., Kaye, S. B., Schellens, J. H., de Bono, J. S.
Published in Journal of clinical oncology (20.06.2007)
Published in Journal of clinical oncology (20.06.2007)
Get full text
Journal Article
Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC
Janne, P. A., Schellens, J. H., Engelman, J. A., Eckhardt, S. G., Millham, R., Denis, L. J., Britten, C. D., Wong, S. G., Boss, D. S., Camidge, D. R.
Published in Journal of clinical oncology (20.05.2008)
Published in Journal of clinical oncology (20.05.2008)
Get full text
Journal Article
AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study
Fong, P. C., Boss, D. S., Carden, C. P., Roelvink, M., De Greve, J., Gourley, C. M., Carmichael, J., De Bono, J. S., Schellens, J. H., Kaye, S. B.
Published in Journal of clinical oncology (20.05.2008)
Published in Journal of clinical oncology (20.05.2008)
Get full text
Journal Article